Core Viewpoint - A class action securities lawsuit has been filed against Inspire Medical Systems, Inc. to recover losses incurred by shareholders due to alleged securities fraud during the period from August 6, 2024, to August 4, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed critical information regarding the launch of the new product, Inspire V, which reportedly faced poor demand due to providers having excess inventory and reluctance to adopt the new treatment [3]. - It is alleged that Inspire Medical Systems failed to complete essential tasks for a successful product launch, including training and onboarding for treatment center customers, setting up IT systems, updating insurer claims software, and ensuring Medicare reimbursement was in place [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to visit a provided link to learn about their rights to seek recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a history of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the United States for seven consecutive years [5].

Core Insights - The company reported significant progress in transitioning from the Inspire IV system to the next-generation Inspire V system during the third quarter [1] - Strong patient outcomes associated with the Inspire V device were highlighted, based on a clinical study conducted in Singapore and initial commercial experiences in the United States [1] Group 1 - The third quarter was crucial for the company, marked by challenges and a focus on the transition to Inspire V [1] - The results from the third quarter demonstrated a positive pickup, indicating successful progress in the transition [1] - The outcomes from the clinical study and commercial experience with Inspire V are described as strong, setting a positive outlook for the future [1]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for misrepresentations regarding the market demand and launch of its sleep apnea device, Inspire V, during the specified Class Period [2][6]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Inspire Medical common stock between August 6, 2024, and August 4, 2025 [2]. - Defendants allegedly made materially false and misleading statements about the demand for Inspire V and the company's readiness for its launch, leading to investor damages when the truth was revealed [6]. Group 2: Investor Information - Investors who purchased Inspire Medical common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - To participate in the class action, investors must act before the deadline of January 5, 2026, to serve as lead plaintiff [4]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [5]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the launch of its Inspire V device for obstructive sleep apnea, which reportedly encountered significant demand issues and operational challenges [4][5]. Company Overview - Inspire Medical develops and manufactures an implantable medical device called "Inspire" for the treatment of obstructive sleep apnea, with the latest version being Inspire V, which includes an implanted sensor and neurostimulator designed to enhance respiration during sleep [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, Inspire Medical and its executives made false statements and failed to disclose critical issues, including poor demand for Inspire V and excess inventory at providers, which hindered the transition to the new treatment [4]. - It is alleged that the launch of Inspire V was not successful, as many centers did not complete necessary training and onboarding, and software updates for billing were delayed, impacting the ability to process claims [5]. Impact on Financial Guidance - Following the revelation of these issues on August 4, 2025, Inspire Medical reduced its 2025 earnings guidance by over 80%, leading to a more than 32% decline in the company's stock price [5]. Legal Process for Lead Plaintiff - Investors who purchased Inspire Medical common stock during the class period have until January 5, 2026, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone, and is recognized for securing significant monetary relief in class action cases [7].

Core Viewpoint - Inspire Medical Systems, Inc. is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Group 1 - The Law Offices of Frank R. Cruz is conducting an investigation on behalf of investors regarding Inspire Medical Systems [1] - The investigation is focused on possible legal violations by the company that could affect its stock performance and investor returns [1] - Investors who have lost money on Inspire Medical Systems are encouraged to inquire about pursuing claims to recover their losses [1]

Summary of Inspire Medical Systems Conference Call Company Overview - **Company**: Inspire Medical Systems (NYSE: INSP) - **Industry**: Medical Technology, specifically focused on sleep apnea treatment Key Points and Arguments Financial Performance - The company reported a strong quarter following a challenging second quarter due to the transition from Inspire 4 to Inspire 5 systems [4][3] - Patient outcomes from the Inspire 5 device were reported positively from clinical studies in Singapore and initial commercial experiences in the U.S. [4][4] - Over 98% of centers have been trained for Inspire 5, with 90% completing contracting and 75% ready for the Sleep Sync preparation [5][5] Product Transition - The transition from Inspire 4 to Inspire 5 is nearly complete, with most centers now using Inspire 5 [8][7] - The new Inspire 5 system has shown a 20% reduction in surgical time, making it easier for ENTs to perform more procedures [11][12] - The removal of the pressure-sensing lead in Inspire 5 has simplified the procedure, addressing previous discomfort for surgeons [11][12] Market Dynamics - The company is focusing on increasing awareness among ENTs and optimizing their practices to handle more cases [15][17] - Inspire Medical Systems is working to ensure consistent reimbursement policies across major payers, which is crucial for physician adoption [24][24] - The transition to a new reimbursement code (64568) has improved reimbursement rates, particularly for ASCs (Ambulatory Surgical Centers) [28][125] Growth Strategy - Inspire Medical Systems has trained over 1,600 ENT surgeons, with a target market of approximately 12,000 general ENTs and 8,000 head and neck specialists [45][46] - The company is optimistic about expanding its reach to general surgeons and enhancing its market penetration [47][47] - The focus is on community-based care, where the majority of procedures are performed, as these centers drive growth [30][32] Tailwinds and Challenges - The rise of GLP-1 medications has increased awareness of obstructive sleep apnea (OSA), leading to more patients seeking treatment [51][56] - The company anticipates low double-digit revenue growth (10-11%) for the upcoming year, balancing tailwinds from Inspire 5 and headwinds from existing Inspire 4 inventory [82][88] Operational Efficiency - Inspire Medical Systems has improved its operational efficiency, leading to a raised EPS guidance for the year [102][105] - The company is restructuring its commercial organization to enhance the effectiveness of territory managers and field clinical reps [108][111] Future Innovations - Inspire 6 is in development, aiming to automate the device's operation based on patient sleep patterns, which could significantly improve adherence to therapy [160][162] - Recent studies indicate improvements in cardiovascular health among patients using Inspire therapy, which could strengthen the case for payer coverage [164][167] Capital Allocation - The company has a $200 million share repurchase authorization, with $50 million already completed, indicating confidence in its stock valuation [152][152] Additional Important Insights - The company is focusing on direct-to-consumer advertising to increase patient awareness and drive demand for Inspire therapy [138][146] - The transition to Inspire 5 is expected to enhance patient outcomes and streamline procedures, which is critical for long-term growth [160][162]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Class Definition - The lawsuit seeks to recover damages for all individuals and entities that purchased Inspire securities between August 6, 2024, and August 4, 2025 [2]. Group 2: Case Details - The Complaint alleges that Defendants made materially false and misleading statements regarding the market demand for Inspire V, claiming it was stronger than it actually was [3]. - It is also alleged that the Company failed to take necessary steps for a successful launch of Inspire V, leading to misleading statements about the Company's readiness [3]. Group 3: Next Steps - Investors who suffered losses in Inspire have until January 5, 2026, to request to be appointed as lead plaintiff in the case [4]. Group 4: Legal Representation - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 5: Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm that has recovered hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Insights - Inspire Medical Systems reported strong third quarter results, driven by robust adoption of the Inspire V system and operational discipline [1] - The company experienced significant growth in patient volume and positive clinical feedback, contributing to an expanding customer base both in the U.S. and internationally [1] - CEO Tim Herbert expressed enthusiasm regarding the performance of the Inspire V system and the positive reception of its simplified procedure and comfort settings [1] Financial Performance - Revenue for Q3 was $224.5 million, exceeding analyst estimates of $220.2 million, representing a 10.5% year-on-year growth [6] - EPS (GAAP) was $0.34, significantly beating analyst estimates of -$0.19 [6] - Adjusted EBITDA reached $44.08 million, surpassing analyst expectations of $24.72 million, with a margin of 19.6% [6] - The company reaffirmed its full-year revenue guidance at $905 million and EPS guidance at $0.95, both exceeding analyst estimates [6] Market Dynamics - Sales volumes increased by 13.6% year-on-year, although this was a decrease from the 23.8% growth in the same quarter last year [6] - Market capitalization stands at $2.38 billion [6] - CEO Tim Herbert indicated expectations for accelerated growth in 2026 following the rollout of Inspire V, with formal guidance to be provided in January [6] Strategic Initiatives - The company is focusing on transitioning high-volume centers to Inspire V by year-end, while some centers may continue using Inspire IV for specific reasons [6] - Inspire Medical Systems is implementing targeted initiatives to engage ENT surgeons and expand provider capacity, with early results anticipated to be more evident in 2026 [6] - The management team is monitoring competitive dynamics closely, noting that competition is still in early stages and has not significantly impacted growth [6]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for misrepresentations regarding the market demand and launch of its sleep apnea device, Inspire V, during the specified Class Period from August 6, 2024, to August 4, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that defendants made materially false and misleading statements about the demand for Inspire V and the necessary steps taken for its launch, leading to investor damages when the truth was revealed [5]. - Investors who purchased common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by January 5, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of misleading statements regarding the launch of its Inspire V device, which has faced significant setbacks and weak demand, leading to a substantial drop in stock price and market capitalization [2][4][6]. Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who suffered losses in Inspire Medical to contact them for discussing legal options [1]. - A federal securities class action has been filed against Inspire Medical, with a deadline of January 5, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Company Performance and Issues - Inspire Medical announced significant setbacks in the launch of its Inspire V device on August 4, 2025, citing delays in training and onboarding at treatment centers [5]. - The company faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025, affecting the ability to bill for procedures [5]. - Inspire Medical reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [6]. Group 3: Market Impact - Following the announcement of setbacks, Inspire Medical's stock price plummeted over 32% in one day, from $129.95 to $87.91, resulting in a loss of approximately $1.2 billion in market capitalization [6].